Araccel Corporation Recognized as # 1 in Frost & Sullivan: US Electronic Clinical Trials Market 2001
(EMAILWIRE.COM, October 09, 2001 ) Horsham, PA– Araccel Corporation announced today that they have received the #1 ranking in the prestigious Frost & Sullivan, US Electronic Clinical Trials Market 2001 Report. Araccel was ranked #1 in Electronic Patient Diaries and #3 in Electronic Data Capture. Mr. Viswanathan Senior Research Analyst and author of the Frost & Sullivan report- noted that Araccel is in a superior position to take advantage of the exploding clinical trials market from both economic and strategic positions.
“With very little outstanding debt and access to cash float through their public trading status in Sweden, Araccel is probably one of the most attractive companies in which to invest. They are currently well above the 5x standard for scrutiny by most late stage venture investors, and may be in a position to significantly expand their large pharmaceutical customer base within the next year,” said Amith Viswanathan, Frost & Sullivan Research Analyst and Author of Frost and Sullivan: US Electronic Clinical Trials Market 2001.
What makes Araccel a standout is that they have grown steadily from their years before the MiniDoc/Technologix merger, with top brandshare and marketshare already being transferred from the ex-MiniDoc EPD system to their Evolution product, ” he added.
“I am very pleased with the ranking of the Frost & Sullivan Report. This is confirmation of our focus on customers and the modular, flexible and scalable features of our technology platform. This ranking is a sound endorsement of all the great people at Araccel who contributed to this evaluation.“ said Jim Conklin, MD, CEO of Araccel Corporation..
About Araccel Corporation:
Araccel Corporation is the U.S. subsidiary of Araccel AB (ARAC B), a Swedish company that is publicly traded on the Nordic Growth Market (NGM). Araccel AB is a global biomedical information technology platform company that provides clinical informatics solutions to the pharmaceutical industry to accelerate drug development. The company develops and markets electronic research and development (e-R&D) pharmaceutical software and system solutions that captures, analyzes and seamlessly integrates silos of data in order to decrease time and cost of development. Araccel Corporation is the market leader in its area and has 15 of the 20 largest pharmaceutical companies on its customer list. Araccel Corporation is headquartered in Horsham, PA. The Araccel Group also has operations in the UK, and The Netherlands. Araccel AB has approximately 2,900 stockholders and is quoted on the NGM Equity list in Stockholm. Stocks are traded via D. Carnegie AB.
Contact: Preston T. Moritz, Director, Global Marketing, Araccel Corporation
215-674-8174 x231, preston.moritz@araccel.com, www.araccel.com
“With very little outstanding debt and access to cash float through their public trading status in Sweden, Araccel is probably one of the most attractive companies in which to invest. They are currently well above the 5x standard for scrutiny by most late stage venture investors, and may be in a position to significantly expand their large pharmaceutical customer base within the next year,” said Amith Viswanathan, Frost & Sullivan Research Analyst and Author of Frost and Sullivan: US Electronic Clinical Trials Market 2001.
What makes Araccel a standout is that they have grown steadily from their years before the MiniDoc/Technologix merger, with top brandshare and marketshare already being transferred from the ex-MiniDoc EPD system to their Evolution product, ” he added.
“I am very pleased with the ranking of the Frost & Sullivan Report. This is confirmation of our focus on customers and the modular, flexible and scalable features of our technology platform. This ranking is a sound endorsement of all the great people at Araccel who contributed to this evaluation.“ said Jim Conklin, MD, CEO of Araccel Corporation..
About Araccel Corporation:
Araccel Corporation is the U.S. subsidiary of Araccel AB (ARAC B), a Swedish company that is publicly traded on the Nordic Growth Market (NGM). Araccel AB is a global biomedical information technology platform company that provides clinical informatics solutions to the pharmaceutical industry to accelerate drug development. The company develops and markets electronic research and development (e-R&D) pharmaceutical software and system solutions that captures, analyzes and seamlessly integrates silos of data in order to decrease time and cost of development. Araccel Corporation is the market leader in its area and has 15 of the 20 largest pharmaceutical companies on its customer list. Araccel Corporation is headquartered in Horsham, PA. The Araccel Group also has operations in the UK, and The Netherlands. Araccel AB has approximately 2,900 stockholders and is quoted on the NGM Equity list in Stockholm. Stocks are traded via D. Carnegie AB.
Contact: Preston T. Moritz, Director, Global Marketing, Araccel Corporation
215-674-8174 x231, preston.moritz@araccel.com, www.araccel.com
Contact Information:
Hayden Communications, Inc.
Theresa Reed
Tel:
Email us
This is a press release. Press release distribution and press release services by EmailWire.Com: http://www.emailwire.com/us-press-release-distribution.php.
Hayden Communications, Inc.
Theresa Reed
Tel:
Email us
This is a press release. Press release distribution and press release services by EmailWire.Com: http://www.emailwire.com/us-press-release-distribution.php.
|
Private Equity, Angel Investing
Equity Alliance / Private Equity, Angel Investing, / IPO, Venture Capital & IR services / Equity Alliance International Equityallianceir.com Penny Stocks to Watch Sign up for hot penny stock picks Gains of 500%+ possible! Premiumstockpicks.com/landing/ Your text Ads & PR Text Ads plus unlimited press releases, One release featured/Day for only $575 per month. Read more on Text Ads & PR Your text Ads Here! Text Ads are only $289 per month. Ads are placed same day. More on Text Ads Advertising |